Marshall Wace’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-50,900
| Closed | -$204K | – | 3119 |
|
|
2025
Q2 | $204K | Buy |
+50,900
| New | +$126K | ﹤0.01% | 2456 |
|
|
2023
Q4 | – | Sell |
-135,783
| Closed | -$570K | – | 2376 |
|
|
2023
Q3 | $570K | Buy |
135,783
+7,876
| +6% | +$40.1K | ﹤0.01% | 1675 |
|
|
2023
Q2 | $712K | Sell |
127,907
-67,190
| -34% | -$397K | ﹤0.01% | 1855 |
|
|
2023
Q1 | $1.12M | Buy |
+195,097
| New | +$516K | ﹤0.01% | 1756 |
|
|
2022
Q1 | – | Sell |
-36,033
| Closed | -$247K | – | 3652 |
|
|
2021
Q4 | $247K | Buy |
36,033
+2,625
| +8% | +$22.7K | ﹤0.01% | 3091 |
|
|
2021
Q3 | $387K | Sell |
33,408
-6,794
| -17% | -$106K | ﹤0.01% | 2528 |
|
|
2021
Q2 | $685K | Sell |
40,202
-11,611
| -22% | -$202K | ﹤0.01% | 1984 |
|
|
2021
Q1 | $1.03M | Buy |
+51,813
| New | +$1.14M | ﹤0.01% | 1640 |
|
|
2020
Q4 | – | Sell |
-12,418
| Closed | -$326K | – | 2016 |
|
|
2020
Q3 | $326K | Buy |
+12,418
| New | +$308K | ﹤0.01% | 1347 |
|
Marshall Wace's INZY Position: Q3 2025 in Review
Marshall Wace sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 50,900 shares — an estimated $204K sold.
Marshall Wace first reported a position in INZY in Q3 2020 and held it in 9 quarters. The position peaked at $1.12M in Q1 2023. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Marshall Wace reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Marshall Wace sold 50,900 Inozyme Pharma shares in Q3 2025, an estimated $204K.
- Marshall Wace first reported a position in Inozyme Pharma in Q3 2020 and held it in 9 quarters.
- Marshall Wace's Inozyme Pharma position peaked at $1.12M in Q1 2023.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Marshall Wace's 13F filing for Q3 2025, filed 13 Nov 2025.